Related Experiment Video
Updated: May 17, 2026
06:59
Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025
Update on diffuse alveolar hemorrhage and pulmonary vasculitis
Megan L Krause1, Rodrigo Cartin-Ceba, Ulrich Specks
1Department of Internal Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.
Immunology and Allergy Clinics of North America
|October 30, 2012
Summary
Diffuse alveolar hemorrhage requires identifying the cause for proper treatment. Antineutrophil cytoplasmic antibody-associated vasculitis is a common cause, with rituximab showing promise in its management.
Area of Science:
- Pulmonology
- Rheumatology
- Nephrology
Background:
- Diffuse alveolar hemorrhage (DAH) presents as a syndrome with diverse etiologies.
- Identifying the specific cause of DAH is critical for guiding effective treatment strategies.
Purpose of the Study:
- To highlight the significance of diagnosing the underlying cause of DAH.
- To emphasize the role of pulmonary vasculitis, specifically antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), as a frequent cause of DAH.
- To discuss current and emerging treatment modalities for AAV-induced DAH.
Main Methods:
- Literature review of DAH and AAV.
- Analysis of treatment protocols for AAV.
- Evaluation of the efficacy of rituximab in AAV management.
Main Results:
- Pulmonary vasculitis, particularly AAV, is a significant contributor to DAH.
- Standard AAV treatment involves induction and maintenance therapy.
- Rituximab is increasingly utilized and effective in treating AAV.
Conclusions:
- Accurate diagnosis of DAH etiology is paramount for patient outcomes.
- ANCA-associated vasculitis is a key differential diagnosis for DAH.
- Rituximab represents a valuable therapeutic option for patients with AAV-related DAH.
Related Concept Videos
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:30Pneumonia III: Complications and Assessment
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
01:18Pulmonary Edema II: Pathophysiology
Pulmonary edema is the accumulation of fluid in the interstitial and alveolar spaces of the lungs, impairing gas exchange and oxygen delivery. It may be cardiogenic or noncardiogenic, but both reduce oxygenation and lung compliance.Cardiogenic Pulmonary EdemaCardiogenic edema results from increased hydrostatic pressure in pulmonary capillaries, usually due to left ventricular dysfunction from myocardial infarction, heart failure, or valvular disease. Ineffective cardiac pumping causes blood to...
01:30Radiological Investigation II: MRI and Ventilation Perfusion Scan
Description
Magnetic Resonance Imaging (MRI) and Ventilation Perfusion Scans are two radiological investigations that offer detailed diagnostic images of the body, particularly lung structures.
MRI
MRI uses magnetic fields and radiofrequency signals to distinguish between normal and abnormal tissues. This technology provides a more detailed diagnostic image than CT scans, enabling it to characterize pulmonary nodules, stage bronchogenic carcinoma, and evaluate inflammatory activity in...
Magnetic Resonance Imaging (MRI) and Ventilation Perfusion Scans are two radiological investigations that offer detailed diagnostic images of the body, particularly lung structures.
MRI
MRI uses magnetic fields and radiofrequency signals to distinguish between normal and abnormal tissues. This technology provides a more detailed diagnostic image than CT scans, enabling it to characterize pulmonary nodules, stage bronchogenic carcinoma, and evaluate inflammatory activity in...
01:27Pulmonary Embolism III: Nursing Management
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...